Send to

Choose Destination
Int J Spine Surg. 2015 Feb 3;9. doi: 10.14444/2002. eCollection 2015.

Prospective analysis of a new bone graft in lumbar interbody fusion: results of a 2- year prospective clinical and radiological study.

Author information

Orthopaedic Surgery, Sint-Trudo ZiekenHuis, Sint- Truiden, Belgium.



This study examined the efficacy and safety of bone graft material ABM/P-15 (iFACTOR) for use in posterior lumbar interbody fusion. ABM/P-15 has been used safely for more than a decade in dental applications.


Forty patients underwent PLIF surgery, with each patient as control. Assessments up to 24 months included radiographs, CT scan, VAS, and ODI. Primary success criteria were fusion and safety.


Intra-cage bridging bone occurred earlier with ABM/P-15 than autograft (97.73% vs. 59.09% at 6 months). On average pain decreased 29 points and function improved 43 points. Radio dense material outside the disk space occurred more frequently with ABM/P-15 than autograft, without clinical consequence.


This study suggests that ABM/P-15 has equal or greater efficacy at 6 and 12 months. Pain improvements exceeded success criteria at all time points. Functional improvement exceeded success criteria at all time points.


This study explores the safety and efficacy of an osteobiologic peptide enhanced bone graft material as a viable alternative to autograft and its attendant risks.


ABM/P-15; P-15; PLIF; bone graft alternative; lumbar fusion; peptide

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center